Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
What brings pericytes to tumor vessels?
Rakesh K. Jain, Michael F. Booth
Rakesh K. Jain, Michael F. Booth
Published October 15, 2003
Citation Information: J Clin Invest. 2003;112(8):1134-1136. https://doi.org/10.1172/JCI20087.
View: Text | PDF
Commentary

What brings pericytes to tumor vessels?

  • Text
  • PDF
Abstract

Paracrine signaling via platelet-derived growth factor B (PDGFB), expressed by endothelial cells, and its receptor PDGFR-β, expressed by pericytes, plays a central role in blood vessel maturation. A new study reveals that it is not just the presence of PDGFB, but how it is presented to pericytes, that determines the quality of the endothelium-pericyte interaction.

Authors

Rakesh K. Jain, Michael F. Booth

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
MC recruitment to tumor vessels depends on a putative gradient of PDGFB....
MC recruitment to tumor vessels depends on a putative gradient of PDGFB. (a) PDGFB, secreted by an EC tube, has higher concentration near the tube, as shown in the small graphs. (b) Normally, MCs, which express PDGFR-β, sense the PDGFB concentration gradient and move in to closely contact the ECs. (The basement membrane is not shown.) (c) If MCs do not express PDGFR-β, then they are not recruited. (d) Modifying PDGFB to remove its matrix retention eliminates the PDGFB concentration gradient and results in poor EC-MC contact. (e) If tumor cells express PDGFB, the PDGFB concentration in the tumor overwhelms the peri-EC gradient and EC-MC contact remains poor. (f) Perivascular cells expressing GFP under the control of the VEGF promoter surround vessels in the tumor interior. The image was obtained using a two-photon microscope. Orange, vessel lumens; green, MCs. Panel f is reproduced with permission from Nature Medicine (8).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts